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Edited by Angel NebredaAbstract Recent evidence indicates that cell-cycle regulating
proteins are involved in apoptotic process in post-mitotic neu-
rons. In this study, we examined cell-cycle regulators for G1/S
cell-cycle progression after a transient focal cerebral ischemia
induced by middle cerebral artery (MCA) occlusion. In the cere-
bral frontoparietal cortex, we observed a marked induction of
Cyclin D1 (a coactivator of Cdks), and proliferating cell nuclear
antigen (PCNA), together with upregulated Cdk kinase activi-
ties. This process is accompanied with multiple phosphorylation
of retinoblastoma (Rb) protein at Cdk phosphorylation sites in
neurons from the ischemic cortex. We further examined DNA
synthesis by the incorporation of BrdU, a nucleotide analog that
incorporates into newly synthesized DNA. Within 24-h of reper-
fusion after 60-min occlusion, substantial BrdU-positive neurons
were observed in the ischemic cortex. Inhibition of Cdk4 activity
during this ischemia/reperfusion is highly neuroprotective. These
results suggest that ischemia/reperfusion cerebral damage
induces signalings at the G1/S cell-cycle transition, and may
constitute a critical step in the neuronal apoptotic pathway in
ischemia/reperfusion induced neuronal damage.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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antigen1. Introduction
In the nervous system, a distinctive property of terminally dif-
ferentiated neurons is their irreversible escape from the cell cy-
cles. However, induction of aberrant cell-cycle regulating
protein is observed in a number of pathological processes in
post-mitotic neurons, including Parkinsons disease (PD),
amyotrophic lateral sclerosis [1] and Alzheimers disease (AD)
[2], together with a number of other neurodegenerative diseases
[3]. These cell-cycle proteins accumulate in dying neurons and
appear to induce neuronal cell death [4,5]. In addition, inhibitors
of Cdks and the expression of dominant-negative forms of Cdk4
andCdk6 suppress neuronal apoptosis [6,7].However, cell-cycle
regulators have not been thoroughly investigated in conditions
of acute neuronal death, such as brain trauma or stroke.*Corresponding author.
E-mail address: jsimpkin@hsc.unt.edu (J.W. Simpkins).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.07.028Cyclin D1 is a member of the G1 cyclin family, which plays a
critical role in the progression of the cell cycle in proliferating
cells by activating Cdk2, Cdk4, or Cdk6. One of the physiolog-
ical substrate of Cyclin D/Cdk complex is the retinoblastoma
(Rb) tumor-suppressor protein, a key regulator for cell-cycle
progression, diﬀerentiation, and the survival of neurons [8].
Rb is composed of several protein-binding domains that inhi-
bit the activity of a variety of cellular proteins required for cell-
cycle progression [9]. When phosphorylated at various sites,
Rb loses the ability to bind and inactivate these regulatory pro-
teins. Rb becomes hyperphosphorylated prior to the G1/S
phase transition and during S and G2 phase in proliferating
cells [10]. In growth arrested, senescent, or terminally diﬀeren-
tiated cells, Rb is depophosphorylated and inhibitory to
mitotic progression. The kinases responsible for Rb phosphory-
lation in vivo may include members of the cyclin-dependent
kinase (Cdk) family, Cdk4 and Cdk6 in association with
D-type cyclins [10].
Experimental middle cerebral artery (MCA) occlusion is a
widely used animal model of ischemic stroke. This procedure
causes a unilateral, large ischemic area that typically involves
the basal ganglion and frontal, parietal, and temporal cortical
areas [11,12]. In the peri-infarct area, delayed neuronal death
is associated with not only acute energy deprivation, but also
a variety of neurotoxic insults including excitotoxicity, reactive
oxygen species (ROS) production, and inﬂammatory responses
[13,14]. In these areas, necrosis and apoptosis are both involved
in neuronal death, and the cause of death may vary in diﬀerent
regions and at diﬀerent time points [15]. Caspase-8 and caspase-
3 are both involved in cortical neurons undergoing delayed cell
death after a focal stroke [16]. There are also reports suggesting
a caspase-independent apoptotic pathway after a stroke [17].
Another important issue that involves cell-cycle progressions
in neurons is the observation of neurogenesis, indicated by
BrdU incorporation to replicating DNA, in dentate gyrus
[18], and cortex [19] after a focal ischemic stroke.
In this study, we systematically examined cell-cycle regulator
(cyclin D1), cell-cycle checkpoint regulator (Rb phosphoryla-
tion), and cell cycle executioner (PCNA) involved in female
ovariectomized (ovx) rats subjected to a transient focal cere-
bral ischemia. We also examined the incorporation of BrdU,
a nucleotide analog that incorporates into newly synthesized
DNA, and its distribution with other cell-cycle proteins and
ischemia induced neuronal apoptosis. Further, in order to
understand the role of cell-cycle regulation in this ischemic in-
sult, we evaluated 219476, a potent Cdk4 inhibitor, in this
model in its neuroprotective activity in vivo.blished by Elsevier B.V. All rights reserved.
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2.1. Animals
Female Sprague Dawley rats were purchased from Charles Rivers
(Wilmington, MA) and maintained in our animal facility in a tempera-
ture-controlled room (22–25 C) with 12-h dark-light cycles. All rats
had free access to laboratory chow and tap water. All animal proce-
dures were reviewed and approved by the University of North Texas
Health Science Centers Institutional Animal Care and Use Committee.
2.2. Chemicals and antibodies
Anti-BrdU; 2,3,5-Triphenyl-2H-tetrazolium chloride (TTC); and
other reagents not speciﬁcally described were purchased from Sigma–
Aldrich (St. Louis, MO). Anti-cyclin D1 and PCNA were purchased
from Santa Cruz (Santa Cruz, CA). Phospho-speciﬁc anti-pRb antibod-
ies were purchased from Cell Signaling (Beverly, MA). 219476: (Calbio-
chem, San Diego, CA) Most common chemicals were from Sigma–
Aldrich, or from other reliable provider, at highest possible purity.
2.3. Ovariectomy
Female rats (8–10 weeks old) were bilaterally ovariectomized using a
dorsal approach. Before surgery, animals were anesthetized with keta-
mine (60 mg/kg) and xylazine (10 mg/kg). A small cut was made
through the skin and the muscle and the ovaries were externalized
and removed to avoid the interference of the estrous cycle, all experi-
mental animals received ovariectomies (OVX) at least two weeks be-
fore of any further surgery.
2.4. Middle cerebral artery occlusion
Animals were anesthetized by an intraperitoneal injection of keta-
mine (60 mg/kg) and xylazine (10 mg/kg). MCA occlusion was per-
formed as previously described [20] with slight modiﬁcation. Brieﬂy,
the left common carotid artery, external carotid artery and internal car-
otid artery were exposed through a midline cervical incision. A 3.0
mono-ﬁlament suture was introduced into the internal carotid artery lu-
men and gently advanced until resistance was felt. The surgical proce-
dure was performed within 20 min, with minimal bleeding. The
suture was kept in place for 60 min and then withdrawn to allow reper-
fusion. Rectal temperature was monitored and maintained between
36.5 and 37 C with a heating pad throughout the procedure. At the de-
sired time after the onset of reperfusion, the animals were decapitated
and the brains were removed. The brains were then either dissected cor-
onally into 2 mm sections using a metallic brain matrix (ASI Instru-
ments Inc., Warren, MI) and stained by incubation in 2% TTC in a
0.9% saline solution at 37 C for 30 min, or the animal is perfused with
Safeﬁx (Fisher), then the brain is furthered dropped ﬁxed, embedded
with paraﬃn and sectioned to 8–10 lm for immunohistochemical anal-
ysis. To evaluate the incorporation of BrdU, BrdU (Sigma) 10 mg/kg
was administered intra-peritoneally 2 h prior to the experimental proce-
dure. Each treatment or vehicle group included 3–6 animals. All ﬁgures
were from animals with 24-h reperfusion unless speciﬁcally indicated.
2.5. 219476 Administration
Rats were anesthetized with halothane and placed in a stereotaxic
device. A surgical stainless steel microsyringe was temporarily inserted
with the following coordinates: anterior–posterior 5 mm, lateral
1.8 mm right from bregma point, and 7.9 mm ventral from the dura,
so that the tip of the syringe needle would be inserted into the third
ventricle [21]. The insertion position was conﬁrmed with post-mortem
dissection. Animals were administered 25 ll of 150 lM 219476 (Cal-
biochem) in 30% 2-hydroxypropyl-b-cyclodextrin (HPbCD) into the
right lateral ventricle over a period of 5 min using a microinjection syr-
inge. The needles were held in position for at least another 30 min to
avoid leaking. Sham treated animals received an equal volume of
30% HPbCD (vehicle). The animals were then allowed to recover from
injection at least 2 h before further MCA occlusion surgery.2.6. DNA fragmentation analysis with TdT-mediated dUTP Nick-End
labeling
TdT-mediated dUTP Nick-End labeling (TUNEL) staining was
performed according to the manufacturers instructions [22]. Forma-
lin-ﬁxed, paraﬃn-embedded tissue sections were deparaﬃnizated withxylene, rehydrated through graded ethanol treatment, and given a ﬁnal
wash in PBS. Sections were then washed and treated for 15 min with
100 lg/ml proteinase K in PBS, equilibrated with equilibration buﬀer
for 10 min, and then incubated with buﬀer containing TdT enzyme
and FITC-labeled dUTP (Promega, Madison, WI) at 37 C in a
humidiﬁed chamber. The reaction was terminated by incubation in
2· SSC buﬀer for 15 min at room temperature. The sections were then
either mounted with anti-fade reagents containing DAPI (Molecular
Probes, Eugene, OR) or received further immunoﬂuorescent staining.
Positive control sections were immersed in DNase I solution for
10 min at room temperature before equilibration in TdT buﬀer. The
sections were observed under a ﬂuorescent microscope with appropri-
ate excitation/emission ﬁlter pairs.
2.7. Immunohistochemical staining
Sections for immunohistochemical staining were stained with either
immunoﬂuorescence, or HRP-conjugated polymer with DAB substrates
(Zymed, South San Francisco, CA). Formalin-ﬁxed and paraﬃn-embed-
ded sections received deparaﬃnation and rehydration treatments similar
to those described previously for TUNEL staining. The sections were
then blockedwith 5%normal goat serum in 1%BSA for 30 min and incu-
bated with appropriate primary antibodies for 60 min at room-tempera-
ture in a humidiﬁed chamber.After being rinsed three times withPBS, the
slides were incubated with species-speciﬁc secondary antibodies conju-
gated to Alexa488 or Alexa633 (Molecular Probes) for 40 min. The sec-
tions were then washed, counterstained, and mounted. Fluorescence
was observed under a laser scanning confocal Leica TCS SP2 Microsys-
tems for analysis using excitation/emission whose wavelength is compat-
ible with each ﬂuorophore. Images were taken on three diﬀerent channels
and processed using Leica Confocal Software (LCS).
Double labeling of TUNEL and other antigens was achieved by
using secondary antibodies labeled with ﬂuorophores that have non-
overlapping spectra. Detection was achieved by using a microscope
with compatible ﬁlter sets or confocal microscopy. Some sections were
nuclear counter-stained with DAPI.
2.8. Semi-quantitative cell counting
To estimate the density of cortical cells labeled with speciﬁc antibod-
ies, methods were adapted from previous reports [23]. Brieﬂy, ischemic
brain sections (n = 6) were randomly selected from paraﬃn-embedded
sections from 4 to 6 mm from anterior surface. Each brain section was
labeled for a speciﬁc antigen (BrdU), or double-labeled with multiple
antigens, together with DAPI-based counter-stain.
Cell counting was performed in the ischemic boundary cortex under a
CAST-Grid system (Nikon). The region was delineated in the ischemic
brain cortex close to the edgeof the surface.The striatumwasnot included
in this study, as few positive cells were observed, and cell types were diﬃ-
cult to identify clearly. Within these boundaries, optical dissectors were
systematically randomly sampled and the number of positive cells was
counted. The positive labeled cell numbers in the investigated region are
normalized with the total number of cells, indicated by the DAPI stain
in ﬂuorescent immunolabeling. The data are expressed as the percentage
of total cells, or expressed directly as number of counts per mm2.2.9. Immunoblot analysis
Tissues were weighed and homogenized with a high speed polytron
in the presence of 10-fold volume of lysis RIPA buﬀer (1· PBS, 1%
Igepal CA-630, 0.5% sodium deoxycholate, 1 mM Na3VO4, 10 mM
NaF, 10 lg/ml aprotinin, 1 lg/ml leupeptin, 1 mM PMSF) containing
protease and phosphatase inhibitors . Protein concentrations were
measured with a Bradford assay. Samples were boiled in SDS–PAGE
loading buﬀer for 5 min. Samples of 30–50 lg were loaded onto
8–16% gradient precast SDS–PAGE gels and separated based on
molecular size. Tissues were weighed and harvested with high speed
polytron into 10-fold protease and phosphatase inhibitor containing
lysis RIPA buﬀer (1· PBS, 1% Igepal CA-630, 0.5% sodium deoxy-
cholate, 1 mM Na3VO4, 10 mM NaF, 10 lg/ml aprotinin, 1 lg/ml
leupeptin, 1 mM PMSF). Protein concentrations were measured with
a Bradford assay. Samples were boiled in SDS–PAGE loading buﬀer
for 5 min. Samples of 30–50 lg were loaded onto 8–16% gradient pre-
cast SDS–PAGE gels and separated based on molecular size. Pre-
stained molecular size markers were used as molecular mass
standards. The gels were then electroblotted onto polyvinylidene
diﬂuoride (PVDF) membranes. Immunodetection of the protein of
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milk in PBST (1· PBS, 0.02% Tween 20) and then adding the pri-
mary antibody with the speciﬁed dilution in blocking buﬀer. The
PVDF membranes were then probed with HRP-conjugated second-
ary antibodies. Positive signal was determined by enhanced chemilu-
minescence, and the speciﬁcity was determined by the apparent
molecular weight of the target protein.
2.10. In vitro kinase assay
Frontoparietal cortex from either ischemic (n = 4) or contralateral
brain (n = 4) was dissected and homogenized in modiﬁed RIPA buﬀer
(1· PBS, 1% Nonidet P-40 or Igepal CA-630, 0.5% sodium deoxycho-
late, 1 mM sodium orthovanadate, 10 lg/ml Aprotinin, 100 lg/ml
PMSF). Samples were incubated on ice for 20 min and then centri-
fuged at 12000 · g for 20 min. Supernatant was collected for further
kinase activity analysis or immunoblotting.
For phosphorylation reaction, 1 lg recombinant human Rb protein
(Sigma–Aldrich) and 10 lg brain extracts were added to reaction buf-
fer, containing 50 mM HEPES, 0.1 mM EDTA, 0.1 mg/ml BSA, 0.1%
b-mercaptoethanol, 0.15 M NaCl, 50 lM ATP, 1 lCi 32P-labeled
c-ATP (ICN Biomedicals Inc., Irvine, CA). The tube was incubated
for 30 min in a 30 C water bath with moderate shaking. SDS–PAGE
loading buﬀer was then added, and the tube was boiled for 10 min to
terminate the reaction. Samples from the phosphorylation reaction
were separated on 10% or 8–16% gradient SDS–polyacrylamide gels.
The gels were stained with Coomassie Brilliant Blue R250 and then
subjected to autoradiography.
2.11. Densitometric analysis
The images of immunoblotting were digitized and imported using a
calibrated scanner at 16-bit gray mode to provide 65535 gray levels.
The area density was quantiﬁed using Labworks software (UVP Inc.,
Upland, CA). The unit given is an arbitrary unit that stands for the
total units per band in the analyzed samples.2.12. Statistical methods
The results were assayed with one-way ANOVA using Prism soft-
ware (Graphpad Inc., San Diego, CA). The signiﬁcance of diﬀerences
among groups was determined by one-way analysis of varianceFig. 1. Induction of apoptosis by transient cerebral ischemia in OVX rats. T
occlusion followed by 24-h reperfusion: (A) contralateral cortex, (B) ischem
ischemic from fully perfused area. Speciﬁcally, blue indicates DAPI counter-s
the merged image of DAPI and TUNEL. (D) TTC-stained brain section
approximate region of A–C. Scale bar = 100 lm.(ANOVA) followed by Tukeys multiple comparison tests. For com-
parisons between two groups, two-tailed Students t tests were used.
P < 0.05 was considered signiﬁcant, with n = 4–7. All values were
expressed as means ± S.E.M.3. Results
3.1. Evaluation of brain damage and apoptosis induced by MCA
occlusion
MCA occlusion is a widely used focal ischemic stroke model
[24]. This in vivo model for neuronal death can induce a syn-
chronized apoptotic process starting from as early as 4 h after
reperfusion [25]. We examined the eﬀects of this transient
ischemia on apoptosis, by analyzing DNA fragmentation with
TUNEL assay. After 24-h of reperfusion, TUNEL-positive
cells were widely detected in the ischemic region, including
the peri-infarct area in the frontoparietal cerebral cortex
(Fig. 1B), but they were not detected in the corresponding con-
tralateral regions (Fig. 1A). In the penumbra areas, where the
ischemic region is separated from the fully perfused area by the
lateral ventricle, TUNEL signal was observed only in the ische-
mic side (Fig. 1C). In the striatal regions that received the
strongest ischemia, more than 80% of total cell population
showed positive TUNEL signals in a variety of cell types,
including neurons, astrocytes, glia, and endothelial cells of
blood vessels, as determined by morphological evaluation
(data not shown). The distribution of TUNEL signal was con-
sistent with the result of TTC stained brain slices (Fig. 1D).
3.2. Induction of cell-cycle regulating proteins in the ischemic
cortex
In the cell-cycle regulation, cyclin D1, accumulates and
translocates into nuclear as cells progress from G1 phase toUNEL-stained sections from various brain regions after 1 h of MCA
ic cortex, (C) penumbra area, where the lateral ventricle separates the
tain, and green indicates TUNEL stain. The presented photographs are
that indicates the area of damage. The letters in (D) indicate the
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during cell-cycle progression [26]. PCNA is a component of
DNA replication complex that is regulated by the activation
of S-phase-related Cdks [27]. We used immunohistochemistry
and immunoblotting to investigate expression level, as well
as subcellular distribution of Cyclin D1 and PCNA, in female
OVX rats that received MCA occlusion in the cerebral cortex.
Antibodies against these proteins produced only diﬀused, weak
signals in the contralateral cortex, reﬂecting the lack of prolif-
erating cells in the adult CNS. However, in the ischemic cortex,
there was elevated immunoreactivity in both Cyclin D1 and
PCNA in numerous cortical pyramidal neurons (Fig. 2A and
B). Most of these signals were nuclear localized, indicating
their active status, and the attempt of the cell to re-enter the
cell cycle induced by this transient cerebral ischemia. Further
quantitative immunoblotting analysis conﬁrmed the upregula-
tion of both Cyclin D1 and PCNA (Fig. 2C and D). We
observed an average of 2-fold increase in Cyclin D1 levels
and 2.7-fold increase of PCNA levels in the ischemic cortex.
To further conﬁrm the activation of G1/S kinase complex,
we examined total Cdk activity in vivo. There was a corre-
sponding 2.8-fold increase in the kinase activity using Rb
protein as a substrate in the ischemic cortical extract. TheseFig. 2. Induction of cell-cycle related proteins by transient cerebral ischemia
cortex showing immunoreactivity of Cyclin D1 (A) and PCNA (B) in the con
high magniﬁcation (right panel). Images were taken on the same section
Representative immunoblotting and the corresponding statistical analysis
contralateral and ischemic cortical brain extract. (E) Representative result
substrates. Lanes 1–4 were from the contralateral extracts while lanes 5–8 w
independent experimental animal. Optical density for the autoradiography wobservations indicate that a transient cerebral ischemia induces
the accumulation and translocation of cyclin D1 complex,
resulting in the activation of the corresponding Cdks. This
activation resulted in the accumulation of PCNA, implying
its physiological and pathological relevance. These observa-
tions suggest that the dysregulation and the accumulation of
Cdks of cell cycles are involved in the ischemia/reperfusion
induced apoptosis.
3.3. Transient ischemia induced phosphorylation of Rb protein
To obtain further information about cell-cycle re-entry, we
examined the phosphorylation of Rb protein in vivo. We exam-
ined the phosphorylation of Rb on with immunohistochemistry
and quantitative immunoblotting. We observed an induction in
the phosphorylation of Rb in vivo. Immunohistochemical study
revealed strong signals of Rb phosphorylation in the ischemic
frontoparietal cortex, but not in the contralateral cortex
(Fig. 3A–C). These results were conﬁrmed by immunoblotting
with antibodies speciﬁc for Rb phosphorylated at Ser807/
Thr811 (Fig. 3D). Double immuno-staining of TUNEL and
phospho-Rb indicated substantial co-localizations (Fig. 4),
and suggesting that activation of cell cycle is involved in the pro-
grammed cell death induced by the transient ischemia.. (A, B) Representative coronal sections of the frontoparietal cerebral
tralateral side (left panel), the ischemic side in low (middle panel), and
from contralateral or ischemic regions. Scale bar = 100 lm. (C, D)
on densitometry (n = 5) of cyclin D1 (C) and PCNA (D) in the
s of cdk kinase activity in vivo using recombinant Rb protein as a
ere taken from the ischemic cortical extracts. Each lane represents an
as quantiﬁed with densitometric analysis (C: contralateral; I: ischemic).
Fig. 3. Induction of Rb phosphorylation by transient cerebral ischemia. (A) Representative coronal sections of the frontoparietal cerebral cortex
showing immunoreactivity of Pb phosphorylation at Ser 807/811, in the contralateral side (left panel), and ischemic side in low (middle panel), and
high magniﬁcation (right panel) on the same section. (B, C) Representative coronal sections of the frontoparietal cerebral cortex showing
immunoreactivity of Rb phosphorylation at Ser 780 (B) and Ser 795 (C) in the ipsilateral cortex at high magniﬁcation. Scale bar = 100 lm. (D)
Representative immunoblotting and the corresponding statistical analysis (n = 5) of Rb phosphorylation at Ser 807/811 in the contralateral (left) and
ischemic (right) cortical brain extract (C: contralateral; I: ischemic).
Fig. 4. Co-localization of Rb phosphorylation and apoptosis in vivo. Representative confocal laser-scanning microscopic images in the penumbra
area, with low magniﬁcation (upper panel) and high magniﬁcation (lower panel). Substantial co-localization of phosphorylated Rb with apoptotic
cells in the region was observed (white arrows in merged picture). Green indicates TUNEL stain, and red indicates pRb Ser 807/811, the last image is
the merged image.
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We further examined DNA replication, another critical cell
cycle event, by evaluating the incorporation of BrdU, a nucle-
otide analog that labels newly synthesized DNA. We observed
no evidence of BrdU incorporation in the contralateral cortex
(Fig. 5A). However, in the ischemic cortex, we observed that a
large number of neurons were labeled with BrdU after 24-h ofreperfusion (Fig. 5A and B). Semi-quantitative analysis of
BrdU-positive cells in the cortex indicated that there were
290 ± 19 cells/mm2 BrdU-labeled cells per section in the ische-
mic cortex, while there were fewer than 5 ± 3 cells/mm2 in the
contralateral cortex. We examined the cell types in these BrdU-
labeled cells, and observed that many of these BrdU-positive
cells co-localize with Map2, a mature neuronal marker, and
Fig. 5. Incorporation of BrdU in the ischemic cortex. Representative coronal sections of the frontoparietal cerebral cortex showing
immunoreactivity of BrdU in the contralateral side (left panel) and the ischemic side in low (middle panel), and high magniﬁcation (right panel).
(B) semi-quantitative analysis of BrdU positive cells in the contralateral and ipsilateral cortex. (C) Representative immunohistochemical analysis of
double-stained sections with BrdU (dark brown) and neuronal marker MAP2 (red) in the ischemic cortex.
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examined the distribution of BrdU incorporation with neuro-
nal apoptosis and observed that most of BrdU positive cells
were co-localized with TUNEL staining, indicating their des-
tiny for programmed death induced by the transient ischemia.
Semi-quantitative analysis indicated that 79 ± 3% of BrdU po-
sitive cells were also TUNEL positive (Fig. 6).
3.5. Inhibition of cell cycle is highly neuroprotective
To further understand the role of cell-cycle re-entry in this
ischemia/reperfusion injury, we examined the eﬀects of Cdk4
inhibition in transient cerebral ischemia. 219476 is a potentFig. 6. BrdU incorporation and apoptosis in vivo. Representative confocal
cortical region, with low (upper panel) and high magniﬁcation (lower panel)
the merged image of these three. Scale bar = 100 lm.inhibitor for Cdk4/Cyclin D1 complex (IC50 = 76 nM), and
inhibits other Cdks only at a 10–50-fold higher concentrations
[28,29]. This Cdk4 inhibition is very eﬀective in protecting the
brains against this ischemia/reperfusion injury. Occlusion of
the MCA in vehicle-treated animals resulted in an average
lesion area of 14 ± 2% of the hemisphere, with the lesion local-
ized primarily in both the parietal cortex and striatum and
basal ganglia. However, the 219476-treated animal resulted
in an average lesion area of 7 ± 2% of the hemisphere, with
the lesion localized primarily in the striatum and basal ganglia
basal ganglia (Fig. 7A). TUNEL analysis revealed similar
results, in the cortical areas, the number of apoptotic cellsmicroscopic images of BrdU and apoptotic cells in the frontoparietal
green indicates TUNEL stain, red indicates BrdU, and the last panel is
Fig. 7. Evaluation of Cdk4 inhibition in MCA occlusion. (A) Eﬀects of 219476 on Rb phosphorylation via cyclin D1 inhibition. (B) Representative
pictures of TTC-stained rat brain slices treated with vehicle (left panel) and 219476 (right panel), a potent Cdk4 inhibitor. (C) Representative pictures
of TUNEL stain of vehicle-treated (upper panel) and 219476-treated (lower panel) treated rat brain sections. Blue indicates nuclear DAPI counter-
stain, and green indicates TUNEL stain.
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of the total cells examined in the cortex approximately 5–6 mm
from anterior.4. Discussion
In this study, we observed that a transient focal cerebral
ischemia caused substantial apoptosis in the ischemic cerebral
cortex, which involves cell-cycle related proteins and novel
DNA synthesis. This transient ischemia is accompanied with
an upregulation of Cyclin D1, as well as the activation ofCdk-complex kinase activity. The physiological relevance
was conﬁrmed by examining the pathological induction of
PCNA expression, and other S-phase cell-cycle marker, includ-
ing the phosphorylation of Rb protein, a critical regulator of
S-phase cell cycle. Most of the phosphorylation of Rb protein
appeared to be localized within apoptotic cells, labeled by
TUNEL stain. Novel DNA synthesis, indicated by BrdU
incorporation, was observed in the ischemic cortex. Further,
inhibition of cell-cycle induction by 219476 is highly neuropro-
tective. These results indicate that cell-cycle re-entry is in-
volved in the neurotoxicity, induced by ischemia/reperfusion
insults and may play a critical role in the progress of neuronal
4598 Y. Wen et al. / FEBS Letters 579 (2005) 4591–4599apoptosis. Inhibition of this process is a potential therapeutic
target for stroke therapy.
The death of neurons is a constructive part of shaping the
nervous system during early development. The neuronal loss
during adult life, however, is involved in a variety of pathologi-
cal process, including behavioral disorders and memory loss,
and may account for the death of the organism. It has long been
held that neurons are terminally diﬀerentiated and post-mitotic.
However, several labs have recently provided evidence that an
attempt by the cell to re-enter cell cycle is involved in many in-
stances of neuronal death [1,2,30–32]. These studies suggest
the paradoxical association of cell divisionwith the degenerative
process of cell death. Hindbrain neurons in mice lacking the Rb
tumor suppressor gene are unable to avoid re-entering the cell
cycle and die by apoptosis immediately after their emigration
from the ventricular zone [33]. Additionally, target-deprived
neurons initiated the synthesis of cell-cycle enzymes (Cyclin D
andPCNA), and incorporated BrdU into highmolecular weight
DNA just before dying.During this same developmental period,
if cell-cycle re-entrance is forced by ectopically driving an onco-
gene with a neuronal-speciﬁc promoter, the targeted neurons
will die rather than divide [34,35]. Several in vitro cell death
models have illustrated similar observation [36–39]. Activation
of Cdks is observed in cultured neurons after treatment with
DNA-damaging agents, reactive oxygen species generating
reagents, including b-amyloid peptide, or the deprivation of tro-
phic factors [36,40,41]. In AD [1,31,42–44] and amyotrophic
lateral sclerosis, cell-cycle related proteins appear in neurons
at risk for death. Further, inhibitors ofCdks are neuroprotective
against focal ischemia [45] and global ischemia [45,46]. Our
observation is consistent with the mounting evidence that cell-
cycle re-entry is involved in programmed neuronal death.
Neuronal apoptosis is not a single event, but a process that
includes a number of signaling cascades and that responds to a
variety of stimuli. We found that it is diﬃcult to clearly identify
a causative relationship between neuronal apoptosis and cell-
cycle re-entry. However, our data, together with previous
research, support the hypothesis that cell cycle is part of the neu-
ronal apoptotic process andmay interact with other parameters,
resulting in cell death. These observations also support that neu-
ronal degeneration in the adult organism is accompanied by
apparent cell-cycle involvement. A persistent question that
accompanies these observations is whether the immunocyto-
chemical appearance of cell-cycle enzymes is indicative of a true
cell cycle or only of the dysregulation of enzyme synthesis in
neuronal apoptosis. Direct evidence of DNA replication was
observed in theADbrain [47], but no further evidence of success-
ful cell division was reported. Further evidence for attempted
cell cycles in the neurodegenerative diseases, as well as other
neurological diseases, is needed to understand these phenomena.
We observed evidence of novel DNA synthesis, in the form
of BrdU incorporation, during neuronal apoptosis. Incorpora-
tion of BrdU has long been considered critical evidence of cell
division, and has been used to study neurogenesis in a variety
of physiological and pathological conditions [48–50]. In this
study, a large number of BrdU positive neurons were observed
over a period of 24-h reperfusion in the cortex. However, a
substantial fraction of BrdU-labeled neurons appeared to be
engaged in neuronal apoptosis, suggesting that DNA synthesis
may have a crucial role in the anti- or pro-apoptotic signaling
cascades that are a response to the insults in these terminally
diﬀerentiated neurons, on the other hand, we can not excludethe possibility that BrdU incorporation is simply the response
of substantial DNA repair that responses to the cellular dam-
age. The substantial presence of BrdU in TUNEL positive
cells, suggesting that more caution should be taken in the eval-
uation of neurogenesis that solely relies on the incorporation
of BrdU under pathological conditions, such as stroke and
neurodegeneration [49].
We further evaluated the role of cell-cycle dysregulation in
the ischemic damage, 219476, which inhibits Cdk4/Cyclin D1
complex, is highly neuroprotective. This suggests that cell cycle
is damaging to the pathological condition, and should be con-
sidered pro-apoptotic. This observation is consistent with
other studies using diﬀerent inhibitors against cell-cycle reentry
in a variety of models [36,51].
In summary, this study indicates that neuronal apoptosis
induced by transient focal cerebral ischemia involves the
induction of cell-cycle related proteins and potentially, novel
DNA synthesis. Inhibition of cell-cycle induction is highly neu-
roprotective. This provides valuable information about the
pathogenesis and signal transduction pathways involved in
neuronal apoptosis and could be a good therapeutic target
for the development of neuroprotective strategies in stroke,
as well as other CNS diseases.References
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